3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
9
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Blood Specimen Collection
53
Surveys and Questionnaires
49
Specimen Handling
29
Observation
15
Radiotherapy
14
Magnetic Resonance Spectroscopy
12
Surgical Procedures, Operative
11
Interviews as Topic
11
Data Collection
11
Drug Therapy
9
darolutamide
8
Biopsy
8
palbociclib
7
Watchful Waiting
7
Tomography, X-Ray Computed
7
Standard of Care
7
ribociclib
6
Magnetic Resonance Imaging
6
Bevacizumab
6
trastuzumab deruxtecan
5
Ultrasonography
5
Restraint, Physical
5
Radiofrequency Ablation
5
Patient Reported Outcome Measures
5
Mental Status and Dementia Tests
5
Mastectomy, Segmental
5
Mass Screening
5
Genetic Testing
5
Breath Tests
5
enzalutamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Blood Component Removal
×
90 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled